[en] Emerging preclinical studies support the concept of a transient "normalization" of tumor vasculature during the early stage of antiangiogenic treatment, with possible beneficial effects on associated radiotherapy or chemotherapy. One key issue in this area of research is to determine whether this feature is common to all antiangiogenic drugs and whether the phenomenon occurs in all types of tumors. In the present study, we characterized the evolution of the tumor oxygenation (in transplantable liver tumor and FSAII tumor models) after administration of SU5416, an antagonist of the vascular endothelial growth factor receptor. SU5416 induced an early increase in tumor oxygenation [measured by electronic paramagnetic resonance (EPR)], which did not correlate with remodeling of the tumor vasculature (assessed by CD31 labeling using immunohistochemistry) or with tumor perfusion (measured by dynamic contrast enhanced-magnetic resonance imaging). Inhibition of mitochondrial respiration (measured by EPR) was responsible for this early reoxygenation. Consistent with these unique findings in the tumor microenvironment, we found that SU5416 potentiated tumor response to radiotherapy but not to chemotherapy. In addition to the fact that the characterization of the tumor oxygenation is essential to enable correct application of combined therapies, our results show that the long-term inhibition of oxygen consumption is a potential novel target in this class of compounds. [en] Emerging preclinical studies support the concept of a transient "normalization" of tumor vasculature during the early stage of antiangiogenic treatment, with possible beneficial effects on associated radiotherapy or chemotherapy. One key issue in this area of research is to determine whether this feature is common to all antiangiogenic drugs and whether the phenomenon occurs in all types of tumors. In the present study, we characterized the evolution of the tumor oxygenation (in transplantable liver tumor and FSAII tumor models) after administration of SU5416, an antagonist of the vascular endothelial growth factor receptor. SU5416 induced an early increase in tumor oxygenation [measured by electronic paramagnetic resonance (EPR)], which did not correlate with remodeling of the tumor vasculature (assessed by CD31 labeling using immunohistochemistry) or with tumor perfusion (measured by dynamic contrast enhanced-magnetic resonance imaging). Inhibition of mitochondrial respiration (measured by EPR) was responsible for this early reoxygenation. Consistent with these unique findings in the tumor microenvironment, we found that SU5416 potentiated tumor response to radiotherapy but not to chemotherapy. In addition to the fact that the characterization of the tumor oxygenation is essential to enable correct application of combined therapies, our results show that the long-term inhibition of oxygen consumption is a potential novel target in this class of compounds.
Disciplines :
Oncology Radiology, nuclear medicine & imaging
Author, co-author :
ANSIAUX, Réginald; Université Catholique de Louvain - UCL > Laboratory of Biomedical Magnetic Resonance
BAUDELET, Christine; Université Catholique de Louvain - UCL > Laboratory of Biomedical Magnetic Resonance ; Laboratory of Medicinal Chemistry and Radiopharmacy
JORDAN, Bénédicte; Université Catholique de Louvain - UCL > Laboratory of Biomedical Magnetic Resonance ; Laboratory of Medicinal Chemistry and Radiopharmacy
CROKART, Nathalie; Université Catholique de Louvain - UCL > Laboratory of Biomedical Magnetic Resonance
DEWEVER, Julie; Université Catholique de Louvain - UCL > Laboratory of Pharmacology and Therapeutics
Jain RK. Normalisation of tumor vasculature: an emerging concept in antiangiogenic therapy [review]. Science 2005;307:58-62.
Folkman J. Role of angiogenesis in tumor growth and metastasis [review]. Semin Oncol 2002;29:15-8.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases [review]. Nature 2000;407:249-57.
Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743-50.
Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65:3643-55.
Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K. Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 2005;85:512-21.
Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005;65:1294-305.
Wildiers H, Guetens G, De Boek G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-86.
Segers J, Fazio VD, Ansiaux R, et al. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: Importance of optimal scheduling to exploit the "normalization" window of the tumor vasculature. Cancer Lett. Epub 2006 Jan 17.
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy [review]. Nat Med 2001;7:987-9.
Takamoto T, Sasaki M, Kuno T, Tamaki N. Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival Kobe. J Med Sci 2001;47:181-91.
Fong TA, Shawver LK, Sun L, et al. SU5416 is apotent and selective inhibitor of the vascular endothelial growth factor receptor (FLK-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 1966;26:143-8.
Volpe JP, Hunter N, Basic I, Milas L. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin Exp Metastasis 1985;3:281-94.
Gallez BF, Jordan B, Baudelet C, Misson PD. Pharmacological modifications of the partial pressure of oxygen in tumors. Evaluation using in vivo EPR oximetry. Magn Reson Med 1999;42:627-30.
Baudelet C, Ansiaux R, Jordan BF, Havaux X, Macq B, Gallez B. Physiological noise in murine solid tumor using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys Med Biol 2004;49:3389-411.
Galbraith SM, Maxwell RJ, Lodge MA, et al. Combrestatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
Jordan BF, Gregoire V, Demeure RJ, et al. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002;62:3555-61.
Ansiaux R, Baudelet C, Cron GO, et al. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 2006;12:1276-83.
Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging [review]. Abdom Imaging 2005;30:324-41.
Kan Z, Phongkitkarun S, Kobayashi S, et al. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in rat model. Radiology 2005; 237:151-8.
Dewhirst MW, Sccomb TW, Ong ET, Hsu K, Gross JF. Determination of local oxygen consumption rates in tumors. Cancer Res 1994;54:3333-6.
Song Y, Kim JG, Mason RP, Liu H. Investigation of rat breast tumour oxygen consumption by near-infrared spectroscopy. J Phys D: Appl Phys 2005;38:2682-90.
Crokart N, Radermacher K, Jordan BF, et al. Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res 2005;65:7911-6.
Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995;34:313-6.
Biaglow JE, Manevich Y, Leeper D, et al. MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. Int J Radiat Oncol Biol Phys 1998;42:871-6.
Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002;157:45-51.
Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-9.
Schuuring J, Bussink J, Bernsen HJ, Peeters W, van Der Kogel AJ. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 2005;61:529-34.
Swartz HM, Khan N, Buckey J, et al. Clinical applications of EPR: overview and perspectives. NMR Biomed 2004;17:335-51.
Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43:169-87.